MedX Reports Progress towards DermSecure(TM) Launch in Brazil
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) experienced strong interest for its SIAscopy on DermSecure(TM) platform from physicians and dermatologists in Brazil during the recent 74th Congress of the Brazilian Society of Dermatology held in Rio de Janeiro in September 2019. MedX representatives attended to support the large team of sales reps working with the Company's Brazilian distribution partners at a MedX branded booth at the show, demonstrating the benefits of the platform to the Brazilian dermatologic community in advance of a launch of the product once regulatory approval is attained.
MedX Health Corp. Announces Private Placement Closing
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) announces that, pursuant to a non-brokered Private Placement Offering (the "Placement Offering"), it has completed an initial Closing of 1,286,111 Units on August 29, 2019, to raise $154,333 from accredited investors pursuant to a Private Placement Offering announced on August 28, 2019. Each Unit, priced at $0.12, comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at a price of $0.20 during the period up to two years from the closing date of the placement. The securities issued as a result of the Placement Offering will be restricted from trading for four months following each Closing. The Placement Offering is still open to subscribers, and further subscriptions may be accepted for further Closings. This Closing, and any further Closing of the Placement Offering, is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange. In connection with the first Closing, a cash commission of $6,960 was paid and 58,000 Agent's Warrants were issued.
MedX Health Corp. Announces Non-Brokered Private Placement
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) is pleased to announce that it has obtained Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,667 units at $0.12 per unit ("Unit"), to raise up to $2,000,000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tranches, will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 8% of funds so introduced, and issuance of agent's warrants ("Agent's Warrant(s)") equal in number to 8% of the number of units so subscribed for. Each Agent's Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.12 per Unit, at any time during the period of two years following the Closing.
MedX Health Corp. Announces Second Quarter 2019 Results
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) announced its results for the three and six-months ended June 30, 2019, which are also available on SEDAR (www.sedar.com).
New Guidelines for Patients Suffering From Mucositis or Oral Ulcerations From Head and Neck Cancer Treatment Can Now Be Effectively Treated With MedX's Light Therapy Devices
MedX Health Corp. ("MedX") (TSX-V: MDX) announces it will initiate a targeted marketing campaign following an announcement by a worldwide coalition of researchers and clinicians who have agreed that light therapy is among the most effective interventions for the prevention of oral mucositis and painful ulcers in the mouth and throat resulting from cancer therapy. The Company said this represents a significant sales opportunity in Canada and the United States for MedX's photobiomodulation therapy devices.
MedX Health Signs Distribution Agreement for Canada, USA and Israel
MedX Health Corp. ("MedX") (TSX-V: MDX) announces that it has signed a non-exclusive, performance-based distribution agreement with Group Vida, to distribute MedX's DermSecure(TM) skin cancer assessment technology platform in the USA, Canada and Israel.
MedX Health Corp. Announces First Quarter 2019 Results and Private Placement
MedX Health Corp. ("MedX" or the "Company") (TSX-V:MDX) announced its results for the three-months ended March 31, 2019, which are also available on SEDAR (www.sedar.com).
MedX Health Corp. Announces 2018 Year End Results
MedX Health Corp. ("MedX" or the "Company") (TSX-V:MDX) announced its results for the year ended December 31, 2018, which are also available on SEDAR (www.sedar.com).
MedX Health Signs Exclusive Distribution Agreement to Launch DermSecure(TM) in Brazil, where Skin Cancer is Prevalent
MedX Health Corp. ("MedX") (TSX-V: MDX) announced today that it has signed an Exclusive Distribution Agreement with CBD Vida ("Vida"), to launch a comprehensive, ease-of-access skin scanning/assessment program throughout Brazil, using MedX's DermSecure(TM) Telemedicine platform.